Yi Young-Su
Department of Life Sciences, Kyonggi University, Suwon 16227, Republic of Korea.
Int J Mol Sci. 2024 Dec 24;26(1):27. doi: 10.3390/ijms26010027.
The inflammatory response consists of two stages: priming and triggering. The triggering stage is marked by the activation of inflammasomes, which are cytosolic protein complexes acting as platforms for inflammation. Inflammasomes are divided into canonical and noncanonical categories. Inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), inflammatory lung injury, and pulmonary fibrosis arise from lung inflammation and damage. While the role of canonical inflammasomes in these diseases is well demonstrated, recent findings emphasize the critical roles of noncanonical inflammasomes in regulating inflammation and various inflammatory conditions. Particularly, new studies highlight their involvement in inflammatory lung diseases. This review delves into recent research on the regulatory roles of noncanonical inflammasomes, such as human caspase-4 and murine caspase-11, in lung inflammation and the development of inflammatory lung diseases, as well as the potential for targeting these inflammasomes for new treatments.
启动和触发。触发阶段的标志是炎性小体的激活，炎性小体是作为炎症平台的胞质蛋白复合物。炎性小体分为经典型和非经典型。哮喘、慢性阻塞性肺疾病（COPD）、急性呼吸窘迫综合征（ARDS）、炎症性肺损伤和肺纤维化等炎症性肺部疾病是由肺部炎症和损伤引起的。虽然经典炎性小体在这些疾病中的作用已得到充分证实，但最近的研究结果强调了非经典炎性小体在调节炎症和各种炎症状态中的关键作用。特别是，新的研究突出了它们在炎症性肺部疾病中的作用。这篇综述深入探讨了关于非经典炎性小体（如人类半胱天冬酶-4和小鼠半胱天冬酶-11）在肺部炎症和炎症性肺部疾病发展中的调节作用的最新研究，以及针对这些炎性小体进行新治疗的潜力。
